Business Wire

EGON-ZEHNDER

11.6.2019 09:02:08 CEST | Business Wire | Press release

Share
Global Study from Egon Zehnder Reveals the Challenges Facing the First Generation of Chief Digital Officers

A global study of the first generation of Chief Digital Officers has found that evolving company culture is proving a significant challenge, with the majority (54%) spending more time evangelizing within their business than executing their digital strategy.

Egon Zehnder, the world’s leadership consulting firm, surveyed CDOs in large companies across 20 countries globally, whose combined revenues total $1 trillion, to explore their expectations and experiences and identify the actions leaders should take to accelerate digital transformation within their organizations.

The study, CDO Decoded: The First Wave of CDOs Speaks , also shows there is still little shared understanding of the role and responsibilities of a CDO. While lines of reporting and key responsibilities vary widely, what unites this group is their pioneering status - the overwhelming majority are the first to hold this role in their organization.

“Organizations and - it turns out - CDOs themselves are still working out what it means to be the CDO,” said Lindsay Trout, Global Digital Practice Leader at Egon Zehnder. “It’s clear though that the experiences of this first generation will shape the direction businesses take in the future.”

CDOs also questioned whether a digital-only role will become obsolete over time. Rob Barger, CDO of Georgia-Pacific, said: “I should not exist in this role in five years.”

Key research findings

The challenges of culture change

  • While just 10% of CDOs saw their primary role as evolving company culture, 54% said they spend more time on evangelizing than executing.
  • 80% of respondents found that evolving company culture was either more difficult or much more difficult than they expected. 68% also cited integration of data and breaking down silos.
  • Just 25% CDOs thought their organizations were ready for digital transformation when they were first hired.
  • Executive commitment and company culture were cited as the two most critical factors in achieving digital transformation by 58% and 57% of CDOs, respectively.

Who today’s CDOs are

  • This is a group of pioneers - 84% are the first to hold a CDO role in their organization and 65% have been in the role for three years or less.
  • CDO is a senior role - 63% report directly to the CEO.

The confidence and ambitions of CDOs

  • 42% of CDOs believe their next job would be a CEO role.
  • 50% said the scope of impact was their primary reason for taking on the CDO role.

Recommendations

Egon Zehnder recommends several actions to ensure the success of a CDO, including:

  • Hire evangelists AND executors: If internal culture change will be required, choose a CDO capable of rallying teams and expressing a vision.
  • Make sure the C-suite gets it: The CEO must ensure the C-suite, including the CFO as well as other P&L leaders, understands the CDO role and supports investment in digital transformation.
  • Don’t forget about culture: Nothing happens without organizational buy-in.
  • Give the CDO freedom to build a strong team : Many CDOs build teams that are a combination of new talent and expertise and legacy.
  • Be willing to measure success in different ways: The CDO must have the right to develop and use their own benchmarks, even in parts of the business that they are not in charge of.

Further information

To read the full CDO Decoded report visit www.egonzehnder.com/cdo-decoded

NOTES TO EDITORS

About the 2019 CDO Survey

Egon Zehnder conducted in-depth surveys with 107 CDOs in 20 countries during December 2018.

About Egon Zehnder

Egon Zehnder is the world’s leadership consulting firm, sharing one goal: to transform people, organizations and the world through great leadership.

We know what great leaders can do and are passionate about delivering the best leadership solutions for our clients.

As One Firm, our more than 480 Consultants in 68 offices and 40 countries bring our individual strengths to form one powerful collaborative team.

We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide Board advisory services, CEO search and succession, executive search, executive assessment, leadership development and organizational transformation.

We offer a range of integrated services to support our leadership consulting work, such as: our investment in Zurich, Switzerland-based Sinequanon (SQN), a firm that uses AI and advanced analytics to improve workplace culture and performance, and our strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA based leadership development firm, which delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing.” In addition, we have partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.

We share a commitment and pride in doing work that contributes to successful careers, stronger companies and a better world.

www.egonzehnder.com

Contact:

Media: Jennifer Reingold Global Head of Content P: +1 212-519-6286 Stacy Drumtra US Head of Marketing and Communications P: +1 312-260-8974

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye